Africa’s first COVID-19 vaccine plant receives no orders since launch
The first COVID-19 vaccine plant in Africa is at risk of closure due to lack of demand.
South Africa-based Aspen Pharmacare, who operates the plant, struck a licensing deal to package and sell Johnson & Johnson's COVID-19 vaccine at the end of 2021, with plans to distribute the vaccine around Africa under the name Aspenovax.
However, an Aspen executive confirmed to journalists last week that no orders for Aspenovax have been received, throwing future production into question.
Aspen senior director Stavros Nicolaou told Reuters: ‘If we don't get any kind of vaccine orders, then clearly there'll be very little rationale for retaining the lines that we're currently using for production’.
The issue was first highlighted at a press briefing on April 14, where Africa CDC Director John Nkengasong told journalists that countries are not ordering the vaccine. He added that if this situation continues ‘the risk is very, very high that the company [Aspen] may actually stop producing the J&J COVID vaccines’.
He noted that countries are reluctant to pay for Aspen's vaccine doses because supply issues have eased in 2022 and hundreds of millions of free doses are now widely available.
The launch of Aspen’s vaccine was originally hailed as a ‘transformative moment’ by the World Health Organization (WHO), who said it would help to address inequality in vaccine access.
Negotiations between Johnson & Johnson, Aspen and the African Vaccine Acquisition Trust began in November 2021 and a deal for 400 million doses was agreed in March. Speaking when the deal was announced, Strive Masiyiwa, African Union special envoy on COVID-19, said: ‘It gets us one step closer to securing Africa's future vaccine production and ensures that the gross vaccine inequality we witnessed in the early part of the pandemic is not repeated’.
Although supply has increased significantly this year, Africa has struggled to bring up its vaccination rate- citing issues with cold chain storage, lack of skilled staff and vaccine hesitancy.
According to Africa’s CDC, just under 16% of the population have received two vaccine doses and 1.33% have received the booster. Just 66% of Africa’s vaccine supply has been used so far.
Ramp-up in local vaccine production
Earlier this year, the African Union announced the goal of producing 60% of all vaccines administered in Africa locally by 2040, up from the current 1%. Several plants are being set up to meet this goal.
In March, Moderna announced that it signed a Memorandum of Understanding with Kenya’s government for its first mRNA manufacturing facility in Africa. It stated that it would produce up to 500 million vaccine doses a year for the continent.
BioNTech is also setting up modular mRNA manufacturing facilities in Senegal, Rwanda, and South Africa, while production of the Sinovac COVID-19 vaccine is already underway in Egypt.
After Aspen reported the lack of demand for its vaccine, some public health analysts have raised concerns over the future success of other, similar initiatives.
Aspen senior director Stavros Nicolaou said: ‘If Aspen doesn't get production, what chance is there for any of the other initiatives?’
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance